Literature DB >> 33716455

Comparison of Long-Term Safety and Efficacy of Bioresorbable Scaffolds between Patients with and without Diabetes Mellitus.

Tse-Hsuan Yang1,2, Feng-You Kuo2, Guang-Yuan Mar2, Chin-Chang Cheng1,2,3, Cheng-Chung Hung2, Hisn-Li Liang1, Wei-Chun Huang1,2,3,4,5.   

Abstract

INTRODUCTION: Diabetes mellitus (DM) is a major risk of cardiovascular events. Bioresorbable stent frame materials capable of providing mechanical support and drug-delivery functions have been developed in an attempt to improve long-term outcomes. However, publications about the long-term outcomes of bioresorbable scaffolds (BRS) in DM patients are still limited. The aim of this study was to investigate the long-term safety and efficacy of BRS between patients with and without diabetes.
METHODS: Data regarding BRS placement in consecutive patients receiving percutaneous coronary interventions were collected from the cardiovascular center of a single tertiary medical center from 2014 to 2017.
RESULTS: A total of 138 cases were included and followed up for 4 years. The mortality rate was 1.1% in the non-diabetic group and 4.1% in the diabetic group (p = 0.2542). No cardiac mortality was observed. One patient had an acute myocardial infarction (0.7%) in the non-diabetic group. The rate of target lesion revascularization was 3.4% in the non-diabetic group and 4.08% in the diabetic group. The ratio of target vessel revascularization was 6.74% in the non-diabetic group and 4.1% in the diabetic group.
CONCLUSIONS: This study demonstrated no significant difference in long-term outcomes after BRS implantation between patients with and without diabetes in a single tertiary medical center.

Entities:  

Keywords:  Acute myocardial infarction; Bioresorbable scaffolds; Coronary artery disease; Diabetes; Percutaneous coronary intervention

Year:  2021        PMID: 33716455      PMCID: PMC7953121          DOI: 10.6515/ACS.202103_37(2).20200808A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  16 in total

Review 1.  Late coronary stent thrombosis.

Authors:  Stephan Windecker; Bernhard Meier
Journal:  Circulation       Date:  2007-10-23       Impact factor: 29.690

2.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

Authors:  Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani
Journal:  J Am Coll Cardiol       Date:  2006-05-05       Impact factor: 24.094

3.  Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.

Authors:  Dean J Kereiakes; Stephen G Ellis; Takeshi Kimura; Alexandre Abizaid; Weiying Zhao; Susan Veldhof; Minh-Thien Vu; Zhen Zhang; Yoshinobu Onuma; Bernard Chevalier; Patrick W Serruys; Gregg W Stone
Journal:  JACC Cardiovasc Interv       Date:  2016-12-21       Impact factor: 11.195

4.  Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).

Authors:  Dean J Kereiakes; Donald E Cutlip; Robert J Applegate; John Wang; Manejeh Yaqub; Poornima Sood; Xiaolu Su; Guoping Su; Naim Farhat; Ali Rizvi; Charles A Simonton; Krishnankutty Sudhir; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2010-12-14       Impact factor: 24.094

5.  Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.

Authors:  Patrick W Serruys; Bernard Chevalier; Yohei Sotomi; Angel Cequier; Didier Carrié; Jan J Piek; Ad J Van Boven; Marcello Dominici; Dariusz Dudek; Dougal McClean; Steffen Helqvist; Michael Haude; Sebastian Reith; Manuel de Sousa Almeida; Gianluca Campo; Andrés Iñiguez; Manel Sabaté; Stephan Windecker; Yoshinobu Onuma
Journal:  Lancet       Date:  2016-10-30       Impact factor: 79.321

6.  Long-term outcome of sirolimus-eluting and zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a Danish organization for randomized trials on clinical outcome III substudy).

Authors:  Kevin K W Olesen; Hans-Henrik Tilsted; Lisette O Jensen; Anne Kaltoft; Lars R Krusell; Jan Ravkilde; Evald H Christiansen; Morten Madsen; Per Thayssen; Henrik T Sørensen; Jens F Lassen; Michael Maeng
Journal:  Am J Cardiol       Date:  2014-11-11       Impact factor: 2.778

7.  Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre GHOST-EU Registry.

Authors:  Piera Capranzano; Davide Capodanno; Salvatore Brugaletta; Azeem Latib; Julinda Mehilli; Holger Nef; Tommaso Gori; Maciej Lesiak; Salvatore Geraci; Stelios Pyxaras; Alessio Mattesini; Thomas Münzel; Aleksander Araszkiewicz; Giuseppe Caramanno; Christoph Naber; Carlo Di Mario; Manel Sabatè; Antonio Colombo; Jens Wiebe; Corrado Tamburino
Journal:  Catheter Cardiovasc Interv       Date:  2017-10-25       Impact factor: 2.692

8.  3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial.

Authors:  Dean J Kereiakes; Stephen G Ellis; Christopher Metzger; Ronald P Caputo; David G Rizik; Paul S Teirstein; Marc R Litt; Annapoorna Kini; Ameer Kabour; Steven O Marx; Jeffrey J Popma; Robert McGreevy; Zhen Zhang; Charles Simonton; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2017-10-31       Impact factor: 24.094

Review 9.  Trends in the epidemiology of cardiovascular disease in the UK.

Authors:  Prachi Bhatnagar; Kremlin Wickramasinghe; Elizabeth Wilkins; Nick Townsend
Journal:  Heart       Date:  2016-08-22       Impact factor: 5.994

10.  Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.

Authors:  Thomas R Einarson; Annabel Acs; Craig Ludwig; Ulrik H Panton
Journal:  Cardiovasc Diabetol       Date:  2018-06-08       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.